First, we demonstrated that complete ablation of RAF1 by CRISPR/cas9 genome engineering or RAF1 silencing with shRNA reduces the proliferation of human colorectal cancer cell lines and patient-derived organoids, respectively. Here, RAF1 is linked to colorectal cancer.